Study type: In vivo/preclinical · Status: Verified against declared source
A humanin derivative reduces amyloid beta accumulation and ameliorates memory deficit in triple transgenic mice.
PloS one · 2011
Study scale: To evaluate the effect of HN derivatives in vivo, Abeta injection model was used in the previous studies [23], [29], [30].
Abstract only: Open source record
Product or molecular entity relationships
- Humanin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.
Plain-language verified summary
Question
Not reported in the reviewed source.
Methods
Humanin (HN) is a multi-functional 24-residue peptide (amino acid sequence: MAPRGFSCLLLLTSEIDLPVKRRA) whose cDNA was isolated from an Alzheimer's disease (AD) patient's occipital lobe of brain, a region that remains generally intact in many AD cases [1] (reviews in [2], [3], [4]).
Scale or participants
To evaluate the effect of HN derivatives in vivo, Abeta injection model was used in the previous studies [23], [29], [30].
Key findings
Humanin (HN), a 24-residue peptide, was identified as a novel neuroprotective factor and shows anti-cell death activity against a wide spectrum of Alzheimer's disease (AD)-related cytotoxicities, including exposure to amyloid beta (Abeta), in vitro.
Limitations and uncertainty
Humanin (HN) is a multi-functional 24-residue peptide (amino acid sequence: MAPRGFSCLLLLTSEIDLPVKRRA) whose cDNA was isolated from an Alzheimer's disease (AD) patient's occipital lobe of brain, a region that remains generally intact in many AD cases [1] (reviews in [2], [3], [4]).
Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.